Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma

Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rechallenge after EGFR-TKI-induced pneumonitis have been reported, little is known about post-pneumonitis osimertinib rechallenge. We describe a 69-year-old never-smoking Japanese woman with postoperativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Shingo, Shiroyama, Takayuki, Tamiya, Motohiro, Nasu, Shingo, Tanaka, Ayako, Morita, Satomu, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Hirashima, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805846/
https://www.ncbi.nlm.nih.gov/pubmed/29487786
http://dx.doi.org/10.1016/j.rmcr.2017.12.005

Ejemplares similares

Ejemplares similares